[Septo-optic dysplasia].

Area of Science:

• Pediatric Endocrinology
• Neuro-ophthalmology
• Developmental Pediatrics

Background:

• Septo-optic dysplasia (SOD), first described in 1956, is characterized by optic nerve hypoplasia, midline brain malformations, and variable hypothalamohypophysial dysfunction.
• It represents an infrequent yet treatable cause of significant hepatic and neurological damage in infants.
• Early diagnosis and initiation of hormone replacement therapy are critical for managing SOD.

Observation:

• This report details a female infant diagnosed with SOD following the identification of cholestatic jaundice.
• The patient presented with all three core components: hypothalamohypophysial dysfunction, bilateral optic nerve hypoplasia, and midline brain malformations including transparent septum dysplasia.
• Clinical manifestations included hypernatremic dehydration due to insipid diabetes, nystagmus, and severe psychomotor retardation.

Findings:

• Despite the recognized importance of early diagnosis, SOD is often identified late, increasing the risk of mortality and brain damage.
• Neonatal indicators such as hypoglycemia, micropenis with cryptorchidism, jaundice, and insipid diabetes can suggest SOD.
• Nystagmus and neurological deficits may manifest later, with definitive diagnosis confirmed by neuroimaging (CT/MRI) and hormonal studies.

Implications:

• Delayed diagnosis of SOD in neonates with hypopituitarism can lead to fatal outcomes or irreversible neurological damage.
• Recognizing early clinical clues like neonatal hypoglycemia or jaundice is vital for timely intervention.
• Prompt diagnosis and management, including hormone replacement, can mitigate the severe consequences of SOD.